Please assess the completion status of the following clinical trial:

Trial Title: Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 18 years of age.~* Histologically or cytologically confirmed stage IIIB or IV NSCLC with non-squamous histology~* Recurrent or progressive disease after one prior platinum-based non-pemetrexed chemotherapy treatment for advanced disease with or without maintenance~* Neoadjuvant/adjuvant cytotoxic chemotherapy initiated \< 12 months prior to study randomization will be counted as one prior treatment~* Neoadjuvant/adjuvant cytotoxic chemotherapy initiated ≥ 12 months prior to study randomization will not be counted as one prior chemotherapy treatment~* Use of targeted agents (e.g., monoclonal antibodies or kinase inhibitors) will not be counted as a prior chemotherapy treatment~* Patients with known EGFR-activating mutations or ALK rearrangements should have received treatment with a targeted kinase inhibitor (e.g., erlotinib, crizotinib) and no longer be considered as a candidate for such treatment~* Measurable disease according to RECIST 1.1~* ECOG performance status 0-1~* Resolution to Grade ≤ 1 Adverse Events, of all clinically significant toxic effects of prior therapy~* Adequate hematologic, hepatic, cardiac, and renal function~* Female patients of childbearing potential must have a negative serum or urine pregnancy test, whichever is considered standard by the institution~Exclusion Criteria:~* Diagnosis of small cell carcinoma of the lung, squamous cell carcinoma of the lung or NSCLC NOS~* Prior therapy with pemetrexed~* Inability or unwillingness to take folic acid, vitamin B12 supplementation or corticosteroids~* Inability to discontinue non-steroidal anti-inflammatory drugs for 5 days (long half-life) or for 2 days (short half-life, if CrCL \<80 mL/min) before pemetrexed dosing and until 2 days after pemetrexed dosing~* Leptomeningeal disease or any untreated or symptomatic brain metastases, unless the following criteria are met:~  * brain metastases are stable and have been previously treated with either whole-brain radiotherapy or gamma-knife surgery~ * steroids are currently not required and more than 14 days since last steroid treatment~* Symptomatic pleural effusion (\> CTCAE Grade 1 dyspnea) that is not amenable to drainage~* Treatment with other systemic anticancer therapy within 4 weeks prior to the first dose of study medication~* Treatment with full field radiation therapy within 4 weeks or limited field radiation therapy within 2 weeks prior to the first dose of study medication~* Major surgery within 4 weeks or minor surgery within 2 weeks prior the first dose of study medication~* Elective or a planned major surgery while on study treatment~* Radiation therapy to greater than 25% of the bone marrow~* Clinically significant active infection (e.g. tuberculosis, viral hepatitis, HIV)~* Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct~* Concurrent active malignancy other than adequately treated basal cell or squamous cell carcinoma of the skin or pre-invasive carcinoma of the cervix.~* Pregnant or breast feeding~* Patients who are taking medications that prolong QT interval and have a risk of Torsades de Pointes (Appendix F) or who have a history of long QT syndrome~* Patients who are taking medications that are strong inducers or inhibitors of CYP3A4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TH-302 and pemetrexed (Type: EXPERIMENTAL): TH-302 in combination with pemetrexed
- Placebo and pemetrexed (Type: ACTIVE_COMPARATOR): Matching placebo in combination with pemetrexed

Based on this trial design, predict the completion outcome and termination type (if applicable).